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Abstract. Acute leukemias are a group of aggressive malignant diseases associated with a high 
degree of morbidity and mortality. An important cause of both the latter is infectious 
complications. Patients with acute leukemia are highly susceptible to infectious diseases due to 
factors related to the disease itself, factors attributed to treatment, and specific individual risk 
factors in each patient. Patients with chemotherapy-induced neutropenia are at particularly high 
risk, and microbiological agents include viral, bacterial, and fungal agents. The etiology is often 
unknown in infectious complications, although adequate patient evaluation and sampling have 
diagnostic, prognostic and treatment-related consequences. Bacterial infections include a wide 
range of potential microbes, both Gram-negative and Gram-positive species, while fungal 
infections include both mold and yeast. A recurring problem is increasing resistance to 
antimicrobial agents, and in particular, this applies to extended-spectrum beta-lactamase 
resistance (ESBL), Pseudomonas aeruginosa, methicillin-resistant Staphylococcus aureus 
(MRSA), vancomycin-resistant Enterococcus (VRE) and even carbapenemase-producing 
Enterobacteriaceae (CPE). International guidelines for the treatment of sepsis in leukemia 
patients include the use of broad-spectrum Pseudomonas-acting antibiotics. However, one should 
implant the knowledge of local microbiological epidemiology and resistance conditions in 
treatment decisions. In this review, we discuss infectious diseases in acute leukemia with a major 
focus on febrile neutropenia and sepsis, and we problematize the diagnostic, prognostic, and 
therapeutic aspects of infectious complications in this patient group. Meticulously and thorough 
clinical and radiological examination combined with adequate microbiology samples are 
cornerstones of the examination. Diagnostic and prognostic evaluation includes patient review 
according to the multinational association for supportive care in cancer (MASCC) and 
sequential organ failure assessment (SOFA) scoring system. Antimicrobial treatments for 
important etiological agents are presented. The main challenge for reducing the spread of 
resistant microbes is to avoid unnecessary antibiotic treatment, but without giving to narrow 
treatment to the febrile neutropenic patient that reduce the prognosis. 
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Introduction. Acute leukemia is a group of highly 
malignant blood disorders characterized by clonal 
growth of immature progenitor cells in the bone 
marrow. This infiltration leads to severe 
thrombocytopenia, anemia and leukopenia, and that 
makes fatal within a few weeks this disease if left 
untreated. There are three major groups of acute 
leukemias; acute myeloid leukemia (AML),1 acute 
lymphocytic leukemia (ALL),2 and on very rare 
occasions mixed phenotype acute leukemia (MPAL).3 
The clinical presentation is often similar, although the 
treatment protocols are different, and the diseases can 
only be cured by intensive chemotherapy treatment, 
possibly in combination with allogeneic hematopoietic 
stem cell transplantation (allo-HSCT).1-3 Infectious 
complications continue to be a significant cause of both 
morbidity and mortality in acute leukemia patients. In 
the present article we review the current and update 
knowledge regarding pathophysiology, epidemiology 
and etiology of infectious complication in patients with 
acute leukemia. Finally, we discuss optimal approaches 
to adequate diagnosis and discuss treatment options for 
this demanding patient group.  
 
Pathophysiology and Risk Factors. The clinical 
susceptibility for infections among patients with 
hematological malignancies is multifactorial. The risk 
of development and the severity of infections are 
determinate by a complex interplay between the 
pathogen and its virulence, and the degree of impaired 
defense mechanisms of the host. The risk of infection 
can broadly be divided into (i) disease-associated 
factors, (ii) patient-related factors, and (iii) treatment-
related factors (Figure 1). 
 
Disease-associated Factors. In acute leukemia, normal 
bone marrow function is to more or less extent, 
replaced by abnormal maturation and dysregulated 
proliferative immature cells, resulting in neutropenia 
and impaired granulocyte function.1-3 It is well 
established that quantitative reduction in circulating 
immune cells makes the organisms more susceptibility 
for invasive infections.4 Furthermore, immature 
myeloid cells have the potential to inhibit the antigen-
specific T-cell response.5 The humoral immune system 
is also affected by the disease and its treatment, so the 
majority of patients will have immunoglobulins' 
deficiency. IgG and IgM being the most affected 
immunoglobulins, and humoral defect immunity can 
also be present in patients achieving complete 
remission.6 Finally, the incidence and severity of 
infections and sepsis are very different in AML 
patients compared to ALL patients. Induction treatment 
induces in AML more prolonged neutropenia, which 
favors infectious complications with early deaths, 
significantly more frequent in AML patients compared 
to ALL patients.7-10 
 
Patient-related Factors. Intrinsic properties related to 
the patient itself are also important in the assessment of 
infection risk in patients with acute leukemia. Age 
itself is a major risk for developing infectious 
complications during the treatment of acute leukemia.11 
The natural function of the immune system declines by
 
 
Figure 1. Risk factors for infections in patients with leukemia. The figure summarizes risk factors for infection in leukemia patients, 
which broadly could be divided into disease specific factors, patient related factors, and treatment related factors.  
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age,12 as both the B- and T-cell function will be 
reduced with increasing age.12 In addition, elderly 
patients are often frailer and have comorbidities 
affecting infection susceptibility,11 increasing the risk 
of both morbidity and mortality of the disease and the 
treatment. Although studies have found that older 
patients are not more susceptible to infections,13 one 
must take into account that older patients are often 
treated with milder and less toxic chemotherapy 
regimens affecting infectious risk.11 Age and 
comorbidity burden increase the risk for intensive care 
unit (ICU) admission,14 and severe comorbidity is a 
strong predictor for early death in acute leukemia 
patients, death often caused by infectious 
complications.15 
In recent years, there has also been an increased 
focus on nutrition, and undernourishment is considered 
a critical risk for serious infection complications.16 
Nutritional problems are often linked to the treatment 
of leukemia, as nausea, vomiting, and emesis are 
common treatment side effects. Consequently, reduced 
food intake and weight loss are often 
complementarities to the treatment, and reduced 
nutritional intake increases the risk of serious 
infections. Low initial body mass index (BMI) and 
more pronounced weight loss during treatment courses 
are strong prognostic indicators associated with lower 
survival and both bacterial and fungal infections.17 
Furthermore, global challenges regarding the 
diagnostic and treatment of infectious complications in 
acute leukemia patients are also important to take into 
considerations. For example, for children treated for 
ALL, the rates of infection-associated mortality are up 
to 10-times higher in low- and middle-income 
countries than in high-income countries.18 This is due 
to several underlying factors such as shortage of 
trained personnel, supplies, diagnostic tools, and 
adequate infrastructures as well as undernourishment 
and risk of multiple drug-resistant organisms 
(MDROs).18 Also, in high-income countries, 
socioeconomic status seems to be a risk factor for 
infection and early complications in acute leukemia 
patients.19 Finally, lower early mortality is also 
registered in centers with larger patients’ volume and 
more special cancer centers. It may result from 
differences in the hospital or provider experience and 
supportive care.20,21 
 
Treatment-related Factors. Treatment of acute 
leukemia requires intensive chemotherapy with high 
dose drugs, often in a combination regimen, resulting 
in prolonged neutropenia, often lasting for weeks.1-3 
The risk of developing more serious and complicated 
infections is clearly linked to the degree and duration 
of neutropenia.4 The risk of severe infections is not 
uniform among these patients, and factors associated 
with increased susceptibility for infectious 
complications include prolonged neutropenia,22 use of 
salvage chemotherapy,23 and relapsed disease.24 
However, other factors than the leukopenia itself are 
associated with infectious risk.  
Mucosal barriers separate self from non-self and are 
the first line of defense against external pathogens. 
Epithelia at mucosal surfaces must allow selective 
paracellular flux, and at the same time preventing the 
passage of potentially infectious agents.25 Leukemia 
patients receiving cytotoxic therapy or radiotherapy 
will experience mucosal barrier injury, often termed 
mucositis. The barrier disruption will create an 
entrance point for resident microorganisms, with the 
potential to cause bloodstream infections.26 
Consequently, the infections are typical due to those 
opportunistic pathogens that inhabit the skin, oral 
cavity, and the gastrointestinal tract, rather than more 
conventional pathogens such as Streptococcus 
pneumonia (S. pneumonia) and Staphylococcus aureus 
(S. aureus).27 
Furthermore, gastrointestinal bacterial colonization 
will often be affected during the treatment course of 
acute leukemia, both trough mucosal barrier injuries, 
and the use of broad spectra antibiotics and other 
microbial agents.26,28 This will affect the natural 
bacterial flora of the intestinal tract, often termed the 
microbiota. Decreases in both oral and feces microbial 
diversity are associated with the receipt of carbapenem 
antibiotics.29 Furthermore, loss of microbial diversity 
throughout treatment is associated with the risk of 
infection29 and with a higher risk of mortality in the 
setting of allo-HSCT.30 Clostridium difficile is clearly 
associated with the use of broad spectra antibiotics, and 
the risk of clinical infections is increased among 
leukemia patients and associated with increased 
mortality.31 In addition, the use of antibiotics sets the 
patients for risk for colonization with MDROs.32 
Colonization with MDROs, especially Enterococcus 
faecalis (E. faecalis), Enterococcus faecium (E. 
faecium), and Stenotrophomonas maltophilia (S. 
maltophilia), has been clearly associated with risk of 
infections and non-relapse-related mortality in the 
setting of allo-HSCT in AML patients.33,34 
Colonization in the intestine, previous use of 
antimicrobial therapy, especially beta-lactams and 
cephalosporins, and total length of hospitalization, all 
increases the risk of more for MDROs, including 
extended-spectrum beta-lactamase resistance 
(ESBL)32,35-38  Central venous catheters (CVCs) are an 
essential tool for an appropriate management of 
patients with acute leukemia. However, CVCs are an 
entrance port for bacteria into the bloodstream and a 
potential for bacterial colonization. CVCs increase the 
risk for bloodstream infections, and the infection risk is 
correlated with the numbers of CVC manipulations. 
The patients are especially vulnerable to gram-positive 
infections.39 The rate of central-line associated 
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bloodstream infections is estimated to 2/1000 catheter 
days,40 and delaying CVC placement in 
acute leukemia does not affect the reduction of 
infectious risk.41 In contrast, antiseptic coating of 
intravascular catheters may be effective in decreasing 
catheter-related colonization and subsequent 
infections.42 Early removal of CVCs should always be 
considered for leukemia patients with undocumented 
sepsis.43 Furthermore, in recent years the use of 
peripherally inserted central catheters is increasing and 
is associated with a lower risk of bloodstream 
infections.44 A study from China in the period 2011-
2014 demonstrated that the risk of BSI in the use of 
peripherally inserted central catheters in cancer patients 
was 0.05/1000 catheter days, and the overall risk of 
infections was approximately 1/1000 catheter days.44 
Taken together, all factors related to one of these 
three conditions increase the risk of infections in 
leukemia patients, and proper evaluation of all these 
risk factors should be considered when evaluating 
leukemia patients for prophylaxis and treatment of 
infectious complications. 
 
Ferbril Netropenia and Sepsis. According to the third 
international consensus definitions for sepsis and septic 
shock, sepsis is defined as life-threatening organ 
dysfunction caused by a dysregulated host response to 
infection.45 Organ dysfunction is identified as an acute 
change in the sequential organ failure assessment 
(SOFA) score.46 Septic shock is defined as a subset 
within sepsis in which underlying circulatory and 
cellular/metabolic abnormalities are profound enough 
to increase the mortality risk substantially. Bacteremia 
is defined as the growth of bacteria in blood cultures, 
although infections do not have to be proven to 
diagnose sepsis at the onset. These criteria also define 
sepsis in patients with acute leukemia. These patients 
are especially prone to bacterial infections following 
chemotherapy due to severe neutropenia,47,48 and their 
cellular immune defect represents an additional 
predisposition to infections to fungi, parasites, and 
viruses. However, leukemic patients are at risk for 
infectious diseases and can present altered symptoms 
and signs due to an impaired inflammatory response. 
Thus a high index of suspicion is warranted.  
 
Clinical Presentation and Diagnosis. Leukemic 
patients may present altered symptoms and signs for 
sepsis and infections because of an impaired 
inflammatory response, thus discovering an infection, 
and the likely focus might represent a major challenge. 
However, sepsis should be suspected in patients 
presenting typical signs and symptoms for infections49 
including fever (core temperature >38°C), hypothermia 
(<36°C), heart rate >90 beats per minute, tachypnea 
(>30 breaths per minute), altered mental status, 
significant edema or positive fluid balance (>20 ml/kg 
over 24 hours), or hyperglycemia (plasma glucose 
>110 mg/dl or 7.7 mmol/l) in the absence of diabetes. 
Besides, one should be aware of organ-specific 
symptoms associated with infectious diseases such as 
respiratory symptoms (cough, rhinorrhea, and 
respiratory distress), gastrointestinal symptoms (nausea, 
vomiting, diarrhea, and abdominal pain), and 
consciousness disturbance which all should lead to 
further diagnostic work-up. Notably, mucositis and 
cutaneous signs such as rash, local heat, swelling, 
exudate, fluctuation, or ulceration can manifest 
infectious diseases in the leukemic patient.  
These latter signs will determine the likely source of 
infection and the status of the organ function. The 
Multinational Association for Supportive Care in 
Cancer (MASCC)-score, Talcott's classification and the 
clinical index of stable febrile neutropenia (CISNE) 
tool could help the assessment of the patients' risk for 
developing a serious infection in patients with febrile 
neutropenia.50 MASCC-score index of <21 indicates a 
low risk, and the patient could be considered for 
outpatient treatment with oral antibiotics. With high 
risk (MASCC>21) or clinical suspicion of sepsis, the 
patient should always be admitted to the hospital.50 
However, it is important to be aware that only a 
minority of the patients (28%) in the original MASCC-
cohort were patients with acute leukemia.51 Direct 
comparison between CISNE and MASCC-score 
demonstrates that CISNE gives a more specific 
identification of low-risk patients, although with lower 
certainty in patients with acute leukemia.52 The 2016 
3.0 sepsis definition recommended qSOFA as a 
screening tool for patients with suspected sepsis. 
qSOFA has so far shown inferior sensitivity compared 
to MASCC-score for risk assessment for sepsis 
development in neutropenic patients.53,54 Cautious use 
of scoring systems, and still be clinical vigilant is 
important, as more validation of these scoring systems 
are needed, also in leukemia-cohorts.  
Hemodynamic parameters can indicate organ 
dysfunctions and sepsis development; arterial 
hypotension (systolic blood pressure <90 mmHg, mean 
arterial pressure <70 mmHg, or a systolic blood 
pressure decrease of >40 mmHg in adults or <2 
standard deviations (SD) below normal for age), mixed 
venous oxygen saturation >70%, cardiac index >3.5 
l/min/m2, arterial hypoxemia (PaO2/FiO2<300), and 
acute oliguria (urine output <0.5 ml/kg/h or 45 ml for 
at least 2 h).  
Laboratory testing helps estimate the severity of the 
infection and may indicate the source of infection.49 
Inflammatory markers indicating sepsis are 
leukocytosis (white cell counts (WBC) >12 x 109/l), 
leukopenia (WBC <4 x 109/l), normal white cell counts 
with >10% of immature forms, and plasma C-reactive 
protein (CRP) or procalcitonin >2 SD above the normal 
value/range. Organ dysfunction can also easily be 
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verified in laboratory testing including creatinine 
increase ≥0.5 mg/dl, coagulation abnormalities 
(international normalized ratio (INR) >1.5 or activated 
partial thromboplastin time (APTT) >60 seconds), 
thrombocytopenia (platelet count <100 000/µl), and 
hyperbilirubinemia (plasma total bilirubin >4 mg/dl or 
70 µmol/l). Hyperlactataemia (>3 mmol/l) can indicate 
decreased tissue perfusion.  
Appropriate cultures and Gram-stains (blood, 
sputum, urine, fluids, and cerebrospinal fluid) are 
helpful to identify the source of the infection and reveal 
the microbe. Blood cultures should ideally be taken 
during fever and before the onset of antibiotics, and are 
found positive in 40-60% of patients with septic shock. 
Positive microbial findings can be crucial for the 
correct treatment of the patient. The chest radiograph 
will aid in the diagnosis of pneumonia, empyema, and 
acute lung injury. Abdominal ultrasound or computer 
tomography (CT) scanning is indicated if abdominal 
sepsis is suspected, and magnet resonance imaging 
(MRI) can help find infections in soft tissues. Several 
factors can affect the outcome of FN, including the 
patient's underlying disease, age, patients' clinical 
condition, number of infectious foci, duration of the 
neutropenia, the onset of antimicrobial therapy, 
geographical location, and local profile of 
antimicrobial resistance.55  
Despite advances in antimicrobial treatment, 
bloodstream infections (BSIs) prolong hospital stay, 
increase direct patient care costs, and cause 
considerable mortality.56,57 In neutropenic patients with 
fever of unknown origin, the attack rate for BSI is 
11%–38%.58 Previous studies showed that infections 
were the cause of death for 50%-80% of acute 
leukemia patients, and for 50% of patients with 
lymphoma and solid tumors.59 In Figure 2, we present 
an algorithm for the management of FN in leukemia 
patients, including prognostic, diagnostic, and 
treatment decision work up.  
 
Bacterial Etiology. Infectious complications in 
patients with hematological malignancies occur most 
frequently in patients with chemotherapy-induced 
cytopenia following intensive chemotherapy,60,61 and 
FN is most common in AML patients. The etiology is 
often unknown at the onset of infection.62 Knowledge 
of the prevalence of causative bacteria in neutropenic 
patients with fever is important as infections can 
rapidly progress, and FN patients can become 
hemodynamically unstable, as prompt and rapid onset 
of adequate antimicrobial treatment within one hour is 
recommended.63,64 There are considerable site- and 
region-specific differences in the incidence of resistant 
organisms such as methicillin-resistant S. aureus 
(MRSA) and vancomycin-resistant enterococcus 
(VRE). These local differences may impact the initial 
choice of empiric antibiotic therapy. Therefore, 
knowledge of the general and local epidemiology and
 
 
Figure 2. Risk factors for infections in patients with leukemia. The figure illustrate an algorithm for management of FN in leukemia 
patients, including prognostic, diagnostic and treatment decision work up. Abbreviations: ANC, absolute neutrophil count; C, Celcius; FiO2, 
Fraction of inspired Oxygen; GCS, Glasgow coma scale; L, liter; MAP, Mean Arterial Pressure; MASCC, Multinational Association for 
Supportive Care in Cancer; PaO2, Partial pressure of Oxygen; Pip/tazo, piperacillin/tazobactam; qSOFA, quick Sepsis Related Organ Failure 
Assessment; SOFA, Sequential Organ Failure Assessment.  
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Table 1 Most common bacteria causing infection in acute leukemia patients. The most frequent Gram-positives and Gram-negatives 
causing infections in acute leukemia patients are summarized in the Table. The table presents the most important microbes, their main source 
for entrance and the possible antimicrobial drugs of choice.  












s S. aureus -MSSA 
-MRSA 
CVC, skin [67, 68] 
CoNS CVC, skin [69] 
E. faecalis 
E. faecium GI-tractus, CVC [70] 
C. difficile Lower GI-tractus [71] 
Viridans group streptococcus Oral/GI-tractus [72-75] 













s E.coli GI-tractus, urogenital [70, 76-81] 
Klebsiella spp. GI-tractus, urogenital [70, 76-81] 
A. baumanii Skin, catheters, environment [82] 
P. aeruginosa GI-tractus, environment [70, 83, 84] 
Abbreviations: MRSA: Methicillin-resistant Staphylococcus aureus. MSSA: Methicillin-sensitive Staphylococcus aureus. CoNS: Coagulase-
negative Staphylococcus. VRE: Vancomycin Resistant Enterococci. 
 
resistance profiles is of paramount importance in the 
optimal treatment of febrile neutropenia.65,66 The most 
frequent bacteria causing infections in acute leukemia 
patients are summarized in Table 1.67-84 
Previous studies have documented bloodstream 
infections in 15–38% of patients with hematological 
malignancies.62,85-87 In Europe and the US, Gram-
negative organisms were the most predominant 
pathogens during the 1970s and the 1980s, followed by 
a shift toward Gram-positive organisms.86 In 2000, 
76% of all BSI in the US was associated with Gram-
positive microbes, of which coagulase-negative 
staphylococci (CoNS), viridans streptococci and 
enterococci were the most frequently isolated 
pathogen.87 Recently, a number of reports show a 
tendency towards an increase of Gram-positive 
bacteremia.62,85-87 This is usually attributed to the 
increasing use of indwelling CVCs and the use of 
fluoroquinolone (FQ) prophylaxis which suppresses the 
aerobic Gram-negative organisms of the 
gastrointestinal tract. Mortality is lower in patients with 
Gram-positive bacteremia than in patients with Gram-
negative bacteremia.86 Epidemiological studies of BSI 
rank Gram-negative rods with Escherichia coli (E. 
coli) as the most frequently isolated pathogen.86 More 
recently, the increased incidence of MDROs, such as 
Gram-negative Enterobacteriaceae, has been the scope 
of several papers.88,89 Gram-negative bacteria are 
reported as MDROs if not susceptible to at least three 
of the following antimicrobial categories: 
antipseudomonal penicillins, cephalosporins, 
carbapenems, aminoglycosides or FQs.90 In several 
European countries,> 10% of invasive infections 
caused by E. coli were due to extended-spectrum beta-
lactamases (ESBL).66,91 Pseudomonas aeruginosa (P. 
aeruginosa) is a Gram-negative pathogen associated 
with high mortality, and accounts for approximately 5-
10% of BSI in hematological patients.92 P aeruginosa 
is characterized by several resistance mechanisms; (i) 
intrinsically resistant to antimicrobial agents due to low 
permeability of its cell wall, (ii) genetic capacity to 
express a vast repertoire of resistance mechanisms, (iii) 
become resistant through mutations in regulative 
resistance genes, and (iv) acquire additional resistance 
genes from other organisms via plasmids, transposons 
and bacteriophages.93 
Carbapenem resistance is reported as high as 3-51% 
in different geographical regions of Europe.91 
Acinetobacter has emerged as a significant cause of 
health-care-associated infection in critically ill and 
immunocompromised patients. Mortality rank between 
17-50% and Acinetobacter baumannii (A. baumannii) 
is estimated to be responsible for about 2-12% of 
BSI.91 Oral mucositis, use of CVC and FQ prophylaxis 
increase the risk of Gram positive BSI. The most 
frequent isolated pathogen is staphylococcus spp, 
dominated by CoNS that accounts for about 25%-33% 
of all BSI.94,95 The more virulent, S. aureus is 
responsible for only a smaller proportion of infections, 
accounting for about 5% of BSI.86 The incidence of 
methicillin resistance is higher in CoNS than in S. 
aureus, the median resistance rate of 80% and 56% 
respectively, and >60% of European centers reporting 
more than 50% methicilline-resistance in CoNS.91,92 
Enterococcus spp. is now the third most frequent 
group of pathogens in BSI and affects 10-12% of 
transplant patients. Many centers report a shift from E. 
faecalis to E. faecium, the latter being frequently 
resistant to ampicillin and demonstrate increasing 
resistance to vancomycin (10.4% in 2014 and 14.9% in 
2017).96 The mortality rate is high, and in one study 
from a transplant center in the US, they found a 30-day 
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mortality of 38%.97 Noteworthy, enterococcus spp. in 
general have low virulence, and BSI with enterococcus 
spp. have been clearly associated with severe 
comorbidity, and their direct impact on mortality 
remains unclear.96,98 
The frequency of viridans streptococci in BSI of 
neutropenic patients with cancer has significantly 
increased over the last 10–15 years and now accounts 
for approximately 5 %.87,99 Risk factors in this patient 
population include severe neutropenia, oral mucositis, 
administration of high-dose cytosine arabinoside, and 
concomitant use of antimicrobial prophylaxis with 
either trimethoprim-sulfa or an FQ. Viridans 
streptococci may contribute to acute respiratory 
distress syndrome; in some studies, mortality rates of 
10% have been reported.100 
 
Treatment of Bacterial Infections. FN is a medical 
emergency, and early identification followed by 
diagnostic blood cultures and prompt administration of 
appropriate intravenous antibiotics remains the 
cornerstones in the initial management. Harvesting 
microbiological cultures and source control obtained 
by removal or drainage of the infected foci is 
mandatory. Empiric antibiotic treatment should be 
started within the first hour after the clinical suspicion 
is raised, according to guidelines for neutropenic fever 
and sepsis.50 When a causative microbe is diagnosed, a 
more targeted antibiotic treatment could be possible, 
resulting in more specific and less broad-spectrum 
antimicrobial therapy. The main antibiotics and their 
characteristics are presented in Table 2.50,67,68,70,71,73-
81,101-109 
Adjuvant sepsis-treatment as fluids therapy is 
important in sepsis treatment, although secondary to 
antibiotic treatment and adequate source control.110 
However, optimization of hemodynamically unstable 
patients, including volume support supplemented with 
a vasopressor, inotropic and transfusion of red blood 
cells (RBCs) in case of persistent hypo-perfusion has 
the potential to reduce morbidity and mortality and can 
prolong survival and improve quality of life.45,111 
 
International recommended empiric treatment of
 
Table 2. Main antibiotics for infection treatment. The table the most relevant antibiotics when treating infections in leukemic patients. 
The table present the most used drugs, their antimicrobial specter and main advantages and disadvantages in clinical practice.  








Penicillin Gram-positives Some anaerobes Penicillin G  
Low toxicity 






most E. Faecalis 
Some Gram-negatives 
Ampicillin 
Less resistance driving 
than cephalosporines 









Psedumonas or MRSA 
activity 
Covering both Gram-
positive and Gram- 
negative, but not 





 Beta-lactam alternative 
for susceptible microbes  




 Cephalosporins Pseudomonas 
active 
Gram-negatives 







as first treatment for 
neutropenic fever 
Ceftazidime give 










with MRSA effect 











Broad spectrum,  
also ESBL and 
anaerobes no effect 





driving  [70, 76-81] 















Pip-Tazo good choice 






















Metronidazole Anaerobes C. difficile Metronidazol 





































Often alternative for 
MRSA; enterococci, 
CoNS 
Nephrotoxicity [67, 68] 
Oxazolidinones Gram-positives, MRSA, VRE, CoNS Linezolide 







Daptomycin Gram-positives, MRSA, VRE, CoNS Daptomycin Well tolerated 
Poor oral 
absorption 






P. aeruginosa,  
A. baumanii , CRE 
Colistin  
Polymyxin B  
Nephrotoxicity 
Neurotoxisity [104] 














Abbreviations: ESBL: Broad-Spectrum β-Lactamase-Producing Enterobacteriaceae. CPE: Carbapenemase-Producing Enterobacteriaceae. 
MRSA: Methicillin-resistant Staphylococcus aureus. MSSA: Methicillin-sensitive Staphylococcus aureus. CoNS: Coagulase-negative 
Staphylococcus. VRE: Vancomycin Resistant Enterococci. 
 
neutropenic fever. International recommended empiric 
treatment for FN is initial broad covering with 
pseudomonas acting beta-lactam antibiotic.50,81,90,112,113 
In cases of septic shock, guidelines recommend two 
Gram-negative acting antibiotics, usually a beta-lactam 
and an aminoglycoside. Traditionally a cephalosporin 
or piperazillin-tazobactam is recommended, although 
this is challenged by the rapid spread of MDROs 
making carbapenem treatment necessary.70,76,77 This is, 
however not only the case, as other treatment narrower 
antibacterial spectra are used in some centers.90 The 
emergence of carbapenemase-producing 
Enterobacteriaceae (CPE) also makes the carbapenems 
less secure choice in several parts of the world.78-81 
Escalation or de-escalation strategies are the two main 
approaches for treatment, depending on the clinical 
condition of the patient (Table 3).50,81,90,112,113 In an 
escalation strategy, treatment is initiated with less 
broad coverage, although escalation is performed if the 
patient responds inadequately to the initial treatment. 
With de-escalation strategy, broader antimicrobial 
therapies initiate the treatment, and if the patient’s 
condition improves de-escalation is performed. Both 
strategies depend on the correction of treatment after 
appropriate microbiology results. With the rapid 
increase of MDROs, all centers treating leukemia 
patients should carefully follow and monitor for 
emerging resistant microbes and use the most 
appropriate treatment, given local epidemiology.  
Guidelines used for febrile neutropenia are based on 
best available data, and a challenge is that studies for 
febrile neutropenia are usually not specific for 
leukemia. In Table 4 we have indicated the main 
population in the studies supporting the current 
guidelines. Because patients with solid tumors show 
different phenotypes and different etiology, direct 
interpretation from these studies should be careful. We 
have emphasized the description of the microbiological 
etiology in the previous section because the suspected 
pathogenic microbe is decisive when starting treatment. 
However, both the microbiology and health 
organization varies in different countries, regions and 
departments. Monitoring the local microbiology and 
correction of local guidelines, and always try to choose 
the lesser resistance driving treatment alternative is 
important. Recommendations given in the next section 
reflect this, where the treatment of different resistant 
microbes are described.  
 
Different local resistance patterns require adaptations
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Table 3. Treatment strategies for empiric antibiotic treatment in acute leukemia patients. The table shows the main escalation and de-
escalation therapy in acute leukemia patients, the different patient groups suitable for the different strategies and recommended empiric 
therapy. 












All patients, unless 
criteria for de-escalation 
approach are present 
Anti-pseudomonal cephalosporin (cefepime, ceftazidime) 
or piperacillin-tazobactam. 
 
Other possible options, depending on local epidemiology: 
Ticarcillin-clavulanate 
Cefoperazone-sulbactam Piperacillin + gentamicin 













Increased risk for 
resistant bacteria, such 
as: 
• Colonization with a 
resistant pathogen 
• Previous infection with 
a resistant pathogen 
• Centers in which 
resistant pathogens are 
frequently isolated 
Particularly if presenting 
in severe clinical 
conditions 
Carbapenem (or a new beta-lactam such as 
ceftolozane/tazobactam or ceftazidime/avibactam) 
Combinations, examples 
• beta-lactam + aminoglycoside 
• beta-lactam + coverage of resistant Gram-positives 
• Colistin-based combinations 
[50, 81, 90, 112, 113] 
 
 
Table 4. Treatment options for special problematic microbes. The table shows treatment recommendation for microbes associated with 
special treatment challenges in patients with acute leukemias. The table is based on European (ECIL) and American (IDSA) 
recommendations, and references to relevant studies are given in the table. First line treatments are listed first, while second line alternatives 
are given in parentheses.  
Problematic microbes Recommended antibiotic treatment options References 
Gram-negatives 
ESBL Carbapenems [70, 76, 77, 114] HSCT, C, H, H 
CPE 
Two or more active agent combinations; 
aminoglycosides, polymyxins, tigecycline, 
fosfomycin, and meropenem 
[70, 78-81] HSCT, I, I, 
P. aeroginosa Combination therapy, using beta lactam with aminoglycoside or fluoroquinolone [70, 83, 84]
 HSCT, HSCT, H 




Colistin combination with ampicillin/sulbactam or 





 Glycopeptides; vancomycin and teicoplanin 
(daptomycin, linezolid, and tigecycline) 
[69] HSCT 
MRSA [68] I 
VRE 
Linezolid and daptomycin (Quinupristin–
dalfopristin, tigecycline, fosfomycin, tedizolid, 
oritavancin, dalbavancin and telavancin). 
[70] HSCT 
Abbreviations: ESBL: Broad-Spectrum β-Lactamase-Producing Enterobacteriaceae. CPE: Carbapenemase-Producing Enterobacteriaceae. 
MRSA. CoNS: Coagulase-negative Staphylococcus. VRE: Vancomycin Resistant Enterococci. Indications of febrile neutropenia 
publications’ main weighting/patient cohort are demonstrated: H; Hematological cohorts, L; Leukemia cohorts, HSCT; Hematological stem 
cell transplantation, C; Mixed Cancer (both hematological and solid), I; infections, not neutropenia in general  
 
of the empirical treatment. When a specific pathogen is 
identified, the treatment should be corrected according 
to resistance as long as the microbiology result is 
clinically plausible.81 Before a definitive resistance 
pattern is given, one will direct treatment after the local 
resistance patterns for the identified microbe. Relevant 
antibiotic treatment for unique problematic microbes 
based on the latest European and American guidelines 
are presented in Table 4.68-70,76-84,114,115 
The first choice for treating ESBL is carbapenems, 
beta-lactams with a time-dependent bactericide 
effect.70,76,77 Aminoglycosides might also have an effect, 
although many ESBL-strains harbor resistance to 
aminoglycosides.92 Aminoglycosides have a 
concentration-dependent bactericide effect depending 
on peak-concentration and a rapid bactericide effect, in 
addition, to being synergistic to beta-lactams.103 
CPE requires a combination of at least two 
antibiotics.78-81 The choices are limited and include 
high dose prolonged meropenem, aminoglycosides, 
polymyxins, tigecyclin and fosfomycin, depending on 
the resistance pattern. High dose of meropenem 
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increases the risk for side effects; nephrotoxicity of 
aminoglycosides and polymyxins could be challenging, 
while resistance development during treatment is a 
significant disadvantage for tigecyclin and fosfomycin. 
P. aeruginosa is often susceptible to pseudomonas 
active cephalosporines and piperazillin/tazobactam, 
although it will often develop resistance during 
treatment.70,83,84 Meropenem will also be a suitable 
choice and double coverage with additional 
aminoglycoside should be considered, especially in 
unstable patients and if anti-pseudomas drugs are 
previously used.116 Tobramycin is the recommended 
aminoglycoside, as high dose gentamycin no longer is 
regarded as sufficient even with dosages of 7mg/kg. 
Gentamycin is now proposed to be removed from The 
European Committee on Antimicrobial Susceptibility 
Testing (EUCAST) clinical breakpoints for 
Pseudomonas spp.  
MDRO A. baumani will often be difficult to treat, 
and represent a major challenge in the treatment of 
leukemia patients if present.82 
CoNS are frequently found in catheter infection and 
BSI. Although not always very virulent, CoNS might 
be difficult to treat due to resistance.69 Vancomycin is 
often the first treatment of choice, although treatment 
has to be corrected after susceptibility-pattern. 
Cloxacilline, daptomycin, linezolid, and tigecycline are 
possible alternatives.  
The MRSA incidence is varying from region to 
region, and coverage for MRSA empirically should be 
considered according to local incidence.68 MRSA could 
be treated with vancomycin and daptomycin, although 
newer MRSA-active cephalosporins have been 
developed. Other alternatives are linezolid and 
tigecycline.  
VRE are not very virulent but have a difficult 
susceptibility-pattern.70 Alternative treatments include 
linezolid and daptomycin. Alternatives are 
quinupristin–dalfopristin, tigecycline, fosfomycin, 
tedizolid, oritavancin, dalbavancin and telavancin. 
The net antibiotic consumption in society, both for 
human and animal use is one of the most important 
predictors for the spread of antibiotic resistance.117 
Acute leukemia patients are maybe the most vulnerable 
of all patients, and among the individuals that easiest 
acquire resistant microbes due to their 
immunocompromised state.70 Acute leukemia patients 
are in need of broad antibiotic coverage, although at 
the same time, they are more vulnerable to side effects. 
The ideal treatment should hence be exposure of 
antimicrobial agents with as narrow antimicrobial 
specter for as short time as possible. Faster 
microbiology service has made it possible to faster 
escalation or de-escalation of the treatment, depending 
on the chosen treatment strategy.  
Norwegian antibiotic-recommendations for 
treatment of neutropenic fever are penicillin and 
aminoglycoside contrary to international 
recommendations.72-75 International studies show that 
aminoglycoside treatment increases the risk of 
nephrotoxicity compared to beta-lactam treatment. 
However, studies from countries with a low prevalence 
of MRDOs like Norway, indicate safety with penicillin 
and aminoglycoside empiric treatment, given early 
reconsideration and escalation when necessary.72,74 
However, significant numbers of patients treated with 
this regime need treatment alterations, although overall 
mortality is not increased compared to other studies of 
FN.72 
 
Invasive Fungal Infections. Invasive fungal infection 
(IFI) represent an important cause of treatment failure 
in adults with acute leukemia, and the cumulative 
probability of developing IFI after a diagnosis of acute 
leukemia has been estimated to 11.1% at 100 days.118 
IFI is a major cause of morbidity and mortality in 
patients with acute leukemia, and patients treated for 
hematologic malignancies, and develop a complicating 
IFI, have an estimated cause specific mortality due to 
IFI of 35-38 %.119,120 AML constitutes the hematologic 
malignancy with the highest risk of associated IFI. In a 
report from 2006, Chamilos and coworkers found IFI 
in 314 of 1017 (31%) autopsies of patients diagnosed 
with hematologic malignancies, of which only 25% 
had been diagnosed with IFI while the patients were 
alive.121 
Data from previous studies have demonstrated; (i) 
the incidence of IFIs in patients with hematologic 
malignancies has increased, (ii) over half of IFIs 
emerge during the remission induction 
chemotherapy,122 (iii) higher age, use of corticosteroid, 
ANC <0.1 X 109/L at the time of IFI diagnosis, lack of 
recovery from aplasia, multiple pulmonary 
localizations of infection and presence of indwelling 
catheters all negatively influence outcome of IFI.123,124 
The most frequently isolated yeast and mold spp. in 
patients with acute leukemias are presented in Table 5. 
The incidence of the most common fungal infections in 
patients with acute leukemia has changed in the last 
decade,125 and the incidence of yeast and mold 
infections show epidemiological variations between 
regions, depending on the patient population, risk 
factors and use of antifungal therapy. In certain 
geographical regions, an association between the 
incidence of IFI, prevalent diseases, and host factors 
exists. The occurrence of cryptococcal and 
Pneumocystis jirovecii (P. jirovecii) infections are 
reported in regions with a high prevalence of human 
immunodeficiency virus (HIV),126,127 and diabetes is a 
risk factor for invasive mold infections.128 In mold 
infections, environmental factors predispose patients 
for invasive infections, with hospital outbreaks linked 
to the use of contaminated instruments and devices, 
Blastomycosis is associated with occupational
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Table 5. Major invasive fungal infections in patients with acute leukemia. The table presents the most important fungus, divided in 





































is Rhizopus spp  
Mucor spp  
Rhizomucor spp  
Lichtheimia 





exposure (e.g., forest rangers) and recreational 
activities (e.g., camping and fishing).128,129 
Candida albicans (C. albicans) was most frequently 
isolated in blood cultures in the '80s and '90s.Since the 
introduction of fluconazole prophylaxis in hematology 
units, there has been a gradual shift from C. albicans to 
non-C.albicans strains.130 Candida spp. that are 
fluconazole-resistant (C. krusei) or susceptible–dose-
dependent (C. glabrata) currently account for >80% 
candidiasis episodes in some hematology units.131,132 
A large concurrent surveillance study, Surveillance 
and Control of Pathogens of Epidemiological 
Importance (SCOPE), was used to examine the secular 
trends in the epidemiology and microbiology of 
nosocomial BSIs. They found Candida spp. to be the 
fourth most common isolated pathogen causing BSIs, 
and C. albicans was the overall most frequently 
isolated pathogen.133 Invasive aspergillosis in patients 
with hematologic malignancies and in patients 
undergoing allo-HSCT is still associated with high 
morbidity and mortality.122,134 There have also been an 
increase in non-Aspergillus fumigatus (A. fumigatus) 
spp., and other mold infections, i.e. Fusarium and 
Mucormycosis.135 The emergence of C. auris that show 
resistance to most known antifungals is still not 
frequent, although it might present as a significant 
problem in the future.136 
In a study from Houston, incidence and risk factors 
for breakthrough invasive mold infections (IMI) in 
AML patients receiving remission induction 
chemotherapy were investigated. 17 % of the patients 
had a possible IMI and only 3.7 % a proven diagnosis 
of IMI. The incidence of proven or probable IMI per 
1000 prophylaxis-days was not statistically different 
between anti-Aspergillus azoles and micafungin. Older 
age and relapsed/refractory AML diagnosis were 
associated with IMI on multivariable analysis.137 
Introduction of echinocandins and more recently 
introduced azoles may have contributed to evolve the 
epidemiology of candidiasis, as incidences of both C. 
parapsilosis and C. tropicalis have increased in some 
treatment centers.124,138 
 
Treatemnt of Fungal Infections. Fungal treatment 
could either be empiric, diagnostic driven or 
directed.139 Empiric therapy is used in centers where 
diagnostics are unavailable, and include broad covering 
with antifungal treatment after persisting fever for 5-7 
days in neutropenic patients, despite antibiotic 
treatment. The European Conference on Infections in 
Leukaemia (ECIL)-guidelines recommend either 
caspofungin or liposomal amphotericin B for empiric 
treatment.140 In diagnostic driven treatment, antifungal 
therapy is started if early markers of fungal infections 
are presented. Markers for fungal infection used in 
clinical practice include positive galactomannan (GM)-
test; positive beta-D-glucan (BDG)-test, PCR-
screening and radiological examinations. Directed 
therapy is given patients with proven fungal disease.  
For invasive candidiasis, echinocandins are first line 
treatment, although stepdown treatment to i.e. 
fluconazole, is recommended after susceptibility test 
results are available.141 Voriconazole, or now recently 
added isavuconazole, are first line treatment for 
invasive aspergillosis.140 Isavuconazole has shown non-
inferiority compared to voriconazole, although it has so 
far shown significantly fewer side effects.142 Treatment 
of mucormycosis is challenging and often includes 
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surgical debridement if possible. Liposomal 
amphotericin B is first line treatment.140,143 P. jirovecii 
is normally treated with trimethoprim-sulfa as long as 
the treatment is tolerated.106 Other alternatives for 
treatment of fungal infections, various fungicides and 
their antifungal spectrum and important 
pharmacological properties are presented in Table 
6,140-142,144 and treatment of special problematic fungal 
infections are presented in Table 7.106,140-143 
 
Prophylaxis of Bloodstream Infection and Fever 
During Neutropenia. Patients with acute leukemias 
are at risk of developing severe infections related to 
previously discussed factors (Figure 1). In the absence 
of preventive measures, 48-60% of the patients who 
became febrile have an established or occult 
infection.145 
The use of antibiotic prophylaxis has been discussed 
widely in both Europe and US. According to European 
and American guidelines, FQs have been 
recommended as prophylaxis during chemotherapy-
induced neutropenia in patients with expected 
neutropenic periods above seven days.84 In 
consideration of increased antibiotic resistance, the role 
of FQ prophylaxis has been reevaluated. A meta-
analysis based on two randomized clinical trials and 12 
observational studies published between 2006 and 
2012 concluded with a reduction of cases with BSI, 
although without effect on overall mortality rate. Some 
of the studies also found increased numbers of 
colonization or infections with MDROs.84 
The increased frequency of E. coli resistance with 
increased FQ use is well documented and results 
mainly form mutations in topoisomerase genes or 
changes in the expression of efflux pumps. It may also 
be transmitted by plasmids which can transfer ESBL at 
the same time. The use of FQ has also been linked to 
the proliferation of several other MDROs such as 
MRSA, VRE and C. difficile.146,147 However, patients at 
high risk of FN should be considered for antimicrobial 
prophylaxis, including patients with acute leukemias. 
The risk stratifications should be based on patient 
characteristics, i.e., advanced age, performance status, 
nutritional status, prior FN, comorbidity, and their 
underlying leukemia.148 
In contrast, most patients should not be considered for 
antifungal prophylaxis, except those that are at risk for 
profound protracted neutropenia, i.e.
 
Table 6. Main antifungal treatment options. The table demonstrates the main treatment classes of antifungal therapy; azoles, 
echinocandins and amphotericin. The most important drugs in each class, their main antifungal specter and main advantages and 
disadvantages are presented from left to right. 









C. neoformans  
Good oral bioavailability 
Good CNS penetration 
Substantial drug 
interactions 
Substantial C. glabrata 
resistance 
Fungustatic, not fungicide 
[141] 
Voriconazole 
Aspergillus spp., Candida spp., 
Cryptococcus spp.,Fusarium 
spp. 
Used for treatment of Aspergillus 






in severe disease  
[140] 




Aspergillus spp., Candida spp., 
Cryptococcus spp,  
  













Caspofungin Fungicide: Candida spp.  Fungostatic: Aspergillus spp. 
Alternative for treatment of 
aspergillus 
No dose reduction for renal failure  
Few drug interactions 
Low CNS and bone 




Mikafungin Fungocide: Candida spp.  Fungostatic: Aspergillus spp. 
No dose reduction for renal failure  
Few drug interactions 
Low CNS, eye and bone 




Anidulafungin Fungocide: Candida spp.  Fungostatic: Aspergillus spp. 
No dose reduction for renal failure  
Less drug interactions 
Low CNS and bone 
penetration No urine 
secretion 














Aspergillus spp.  
C. neoformans 
Lipid formulation most widely use 
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Table 7. Treatment options for special problematic fungus. The table shows treatment recommendation for fungus associated with special 
treatment challenges in patients with acute leukemias. The table is based on European (ECIL) and American (IDSA) recommendations, and 
references to relevant studies are given in the table. First line treatments are listed first, while second line alternatives are given in 
parentheses. 
Problematic microbes Recommended antifungal treatment options References 
Invasive fungal 
infections 
P. jiroveci Trimetoprim-sulfa (Primaquine + clindamycin, pentamidine) [106] I 
Candida spp. Ecinocandins (Fluconazole) [140, 141] L, HSCT 
Aspergillus spp. Voriconazole, isavuconazole (Liposomalt amphotericin B, caspofungin) [140] 
L, HSCT 
Mucormycosis Liposomalt Amphotericin B (Posakonazole, combination)  [140, 142, 143] L, HSCT 
Indications of febrile neutropenia publications’ main weighting/patient cohort are demonstrated: H; Hematological cohorts, L; Leukemia 
cohorts, HSCT; Hematological stem cell transplantation, I; infections, not neutropenia in general.  
 
relapsed/refractory AML patients or patients 
undergoing allo-HSCT. These latter patient groups 
should receive prophylaxis with an oral azole or 
parenteral echinocandin.148,149 
 
Other Causes of Persistent Fever and Their 
Management. Occasionally fever may be the only sign 
of an ongoing infection or non-infectious process in 
patients with chemotherapy-induced neutropenia; other 
decisive signs and symptoms of inflammation 
(erythema, swelling, pain, infiltrates) may be absent. 
The febrile response is non-specific, and concomitant 
use of antipyretic drugs (corticosteroids, paracetamol) 
may suppress fever. As FN is a medical emergency, it 
is crucial to accurately substantiate the differential 
diagnosis, as they require different treatment strategies.  
Fever in acute leukemia patients can also be 
attributed to by one of the following reasons; (i) drug 
fever, (ii) tumor fever (iii) thrombosis, or (iv) 
rheumatologic disorders. Drug fever is associated with 
eosinophilia, acute interstitial nephritis, drug-induced 
hepatitis and disappears rapidly after discontinuation of 
the particular drug.150 Tumor fever is one of the most 
common causes of non-infectious pyrexia in febrile 
patients with malignancy, and may also occur in 
leukemia.151 Thrombosis is always important to be 
aware of, as malignancy is a main risk factor for the 
development of thrombosis.152 Rheumatologic 
disorders are also associated with the clinical 
manifestations of a number of solid and hematological 
diseases and represent an important clue during the 
early diagnosis and treatment of the cancer diseases.153 
 
Conclusions. Acute leukemias are a group of 
malignant blood disorders characterized by a serious 
clinical course, and the only treatment with curative 
potential is intensive chemotherapy, possibly combined 
with allo-HSCT. Infections are important 
complications to both the diseases themselves and their 
therapy. Thoroughly diagnostic workup, including 
microbiological sampling, is the fundament of further 
handling and treatment. Improvements in both 
treatment and prophylaxis against both bacterial and 
fungal infections have helped to improve the treatment 
results for acute leukemia patients. On the other hand, 
resistance development to an increasing proportion of 
the antimicrobial agents we have available is of 
considerable concern, and this, in turn, can lead to 
increased morbidity and mortality among leukemia 
patients from infectious complications. Therefore, 
physicians, who are treating this specific patient group, 
must be carefully aware of this increasing problem and 
make thorough considerations when choosing 
antimicrobial therapy. In order to make leukemia 
treatment less toxic, and thereby reduce the risk of 
serious infections, new searches for new and improved 
antimicrobial agents are important to further improve 
treatment outcomes among patients with acute 
leukemia. 
The noteworthy, infectious complication and early 
mortality seem to be declining with time,19 since the 
diagnostic precision, prophylaxis and treatment have 
increased over the past decades. However, this is 
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